Wolfe Research analyst Mike Polark initiated coverage of Beta Bionics (BBNX) with an Outperform rating and $20 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX:
- Positive Developments and Strategic Advancements Drive Buy Rating for Beta Bionics, Inc.
- Beta Bionics Q1 2025 Earnings: Strong Growth and Optimism
- Strong Performance and Growth Potential: Buy Rating for Beta Bionics, Inc.
- Beta Bionics price target lowered to $15 from $20 at Baird
- Positive Developments and Strong Financial Performance Drive Buy Rating for Beta Bionics, Inc.